about the author

Zachary Brennan

Senior Editor

zachary@endpointsnews.com @ZacharyBrennan
Zachary Brennan on LinkedIn

Zachary Brennan is senior editor for Endpoints, covering the US regulatory agency and others around the globe. He previously wrote about the FDA, Covid-19, and the biopharma industry for POLITICO, and was managing editor for the Regulatory Affairs Professionals Society's news publication. A DC-area native, he majored in English at Northwestern University.

author articles

PBM re­form un­like­ly to at­tach to short-term spend­ing bill as shut­down looms

2 days ago
Pharma
FDA+

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

2 days ago
FDA+

Xcov­ery nabs first FDA ap­proval for lung can­cer drug

3 days ago
Pharma
FDA+

Pay­ers gen­er­al­ly meet drug price watch­dog's 'fair ac­cess' stan­dards, re­port says

3 days ago
Pharma
FDA+

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

4 days ago
Pharma
Law

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

5 days ago
Pharma
Law

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

5 days ago
People
FDA+

Hand­ful of 'un­sup­port­ed' drug price in­creas­es added $800M to US costs, ICER claims

Last week
Pharma

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Last week
Pharma
FDA+

UniQure stock dou­bles on FDA 'align­men­t' over ac­cel­er­at­ed ap­proval for Hunt­ing­ton's drug

Last week
Pharma
FDA+

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Last week
R&D
FDA+

Supreme Court de­clines to take PhRMA-Arkansas 340B case

Last week
Pharma
FDA+

Agios' stock drops af­ter dis­clos­ing new liv­er-re­lat­ed safe­ty warn­ing in fil­ing to FDA

Last week
Pharma
FDA+

FDA spells out new ex­pe­dit­ed with­draw­al pro­ce­dures for ac­cel­er­at­ed ap­provals

3 weeks ago
Pharma
FDA+

Biose­cure com­pro­mise could add ex­ec­u­tive re­view process for named com­pa­nies, sources say

3 weeks ago
R&D
FDA+

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

3 weeks ago
Pharma
FDA+

SEC and Kiromic set­tle over biotech's fail­ure to dis­close clin­i­cal tri­al holds ahead of stock of­fer­ing

3 weeks ago
Pharma
Law

Ap­plied Ther­a­peu­tics gets FDA warn­ing let­ter over study of re­ject­ed rare dis­ease drug

3 weeks ago
FDA+

FDA de­fends in­creased use of guid­ance in new re­port to Con­gress

3 weeks ago
FDA+

Min­neso­ta 340B rev­enue dri­ven by hos­pi­tals and high-priced drugs, first state re­port says

4 weeks ago
Pharma

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

5 weeks ago
Pharma
Law

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Last month
FDA+

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Last month
Pharma
FDA+

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Last month
AI
FDA+
1234 Next page Last page
A service from the Financial Times